Amitiza lubiprostone regulatory update

Sucampo submitted an MAA in Japan for Amitiza lubiprostone to treat chronic idiopathic constipation ( CIC). Sucampo and Takeda market the functional fatty acid chloride channel activator in the U.S. ...